|
|
Article: InterMune Announces Second Quarter Financial Results; 2003 Operating Expense Guidance Lowered.
- Article from:
- PR Newswire
- Article date:
- July 29, 2003
CopyrightCOPYRIGHT 2003 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Company Announces Plans for Pivotal Phase III Trial of Actimmune in IPF
BRISBANE, Calif., July 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2003.
For the second quarter of 2003, InterMune recorded total net product sales of $35.7 million, compared to $23.7 million for the same quarter in 2002, an increase of 51%. Net sales of Actimmune(R) (interferon gamma-1b) for the second quarter of 2003 were $33.1 million, compared to $22.6 million in the same period in 2002, an increase of 46%.
"We are pleased to report that product revenues are in line with our ...